A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia

Leuk Lymphoma. 2015 Jun;56(6):1878-80. doi: 10.3109/10428194.2014.974049. Epub 2014 Nov 20.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Drug Administration Schedule
  • Erythema / chemically induced
  • Follow-Up Studies
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
  • Granulocyte-Macrophage Colony-Stimulating Factor / adverse effects
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Middle Aged
  • Remission Induction
  • Rituximab / administration & dosage
  • Rituximab / adverse effects
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Substances

  • Rituximab
  • Granulocyte-Macrophage Colony-Stimulating Factor